Sign Up for Vincent AI
Apotex Inc. v. Janssen Inc.,
5 firm's commentaries
2023 Year In Review: Life Sciences In Canada
"...hypertension) could indeed be soundly predicted, and dismissed Sandoz's appeal. Read the full decision here. Apotex Inc v. Janssen Inc, 2023 FCA 220: A generic's adjusted product monograph can still induce In Apotex v Janssen, the Federal Court of Appeal calls into question the reliance on ..."
Canadian Patent Law 2023: A Year In Review
"...use their own skill and judgment nor that they make an active choice to perform the infringing use. In Apotex Inc v Janssen Inc, 2023 FCA 220, the Federal Court of Appeal held that neither explicit instructions in a product monograph nor the alleged infringer's intention that direct infring..."
Leave To Appeal To The Supreme Court Of Canada Filed In Apotex Inc. V. Janssen Inc. (2024 FCA 9)
"...the second prong of the test, in other two decisions: Teva Canada Limited v Janssen Inc, 2023 FCA 68 and Apotex Inc v Janssen Inc, 2023 FCA 220. This suggests that the Corlac test, and particularly the second prong, may be an area of increasing judicial scrutiny and/or interest. Accordingly..."
Implicit Inducement Of Patent Infringement ' The Federal Court Of Appeal Hands Down Its Ruling
"...the sale of a generic version of a drug that would infringe certain patents in certain circumstances. 2. Apotex Inc. v. Janssen Inc., 2023 FCA 220 (CanLII), para. The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought abo..."
Canadian Patent Law In Review 2023: Notable Cases And Trends For 2024
"...Subject Matter: Canada (AG) v. Benjamin Moore & Co., 2023 FCA 168 Inducement & the "Skinny Label": Apotex Inc. v. Janssen Inc., 2023 FCA 220 Infringement Without an Injunction: AbbVie Corporation v. JAMP Pharma Corporation, 2023 FC 1520 PMPRB Announces Next Steps in Guidelines Consultat..."
Try vLex and Vincent AI for free
Start a free trialExperience vLex's unparalleled legal AI
Access millions of documents and let Vincent AI power your research, drafting, and document analysis — all in one platform.
Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
Start Your 3-day Free Trial of vLex and Vincent AI, Your Precision-Engineered Legal Assistant
-
Access comprehensive legal content with no limitations across vLex's unparalleled global legal database
-
Build stronger arguments with verified citations and CERT citator that tracks case history and precedential strength
-
Transform your legal research from hours to minutes with Vincent AI's intelligent search and analysis capabilities
-
Elevate your practice by focusing your expertise where it matters most while Vincent handles the heavy lifting
5 firm's commentaries
2023 Year In Review: Life Sciences In Canada
"...hypertension) could indeed be soundly predicted, and dismissed Sandoz's appeal. Read the full decision here. Apotex Inc v. Janssen Inc, 2023 FCA 220: A generic's adjusted product monograph can still induce In Apotex v Janssen, the Federal Court of Appeal calls into question the reliance on ..."
Canadian Patent Law 2023: A Year In Review
"...use their own skill and judgment nor that they make an active choice to perform the infringing use. In Apotex Inc v Janssen Inc, 2023 FCA 220, the Federal Court of Appeal held that neither explicit instructions in a product monograph nor the alleged infringer's intention that direct infring..."
Leave To Appeal To The Supreme Court Of Canada Filed In Apotex Inc. V. Janssen Inc. (2024 FCA 9)
"...the second prong of the test, in other two decisions: Teva Canada Limited v Janssen Inc, 2023 FCA 68 and Apotex Inc v Janssen Inc, 2023 FCA 220. This suggests that the Corlac test, and particularly the second prong, may be an area of increasing judicial scrutiny and/or interest. Accordingly..."
Implicit Inducement Of Patent Infringement ' The Federal Court Of Appeal Hands Down Its Ruling
"...the sale of a generic version of a drug that would infringe certain patents in certain circumstances. 2. Apotex Inc. v. Janssen Inc., 2023 FCA 220 (CanLII), para. The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought abo..."
Canadian Patent Law In Review 2023: Notable Cases And Trends For 2024
"...Subject Matter: Canada (AG) v. Benjamin Moore & Co., 2023 FCA 168 Inducement & the "Skinny Label": Apotex Inc. v. Janssen Inc., 2023 FCA 220 Infringement Without an Injunction: AbbVie Corporation v. JAMP Pharma Corporation, 2023 FC 1520 PMPRB Announces Next Steps in Guidelines Consultat..."